[go: up one dir, main page]

CL2018002562A1 - Método para acelerar la involución e impedir la infección de glándulas mamarias en el secado. - Google Patents

Método para acelerar la involución e impedir la infección de glándulas mamarias en el secado.

Info

Publication number
CL2018002562A1
CL2018002562A1 CL2018002562A CL2018002562A CL2018002562A1 CL 2018002562 A1 CL2018002562 A1 CL 2018002562A1 CL 2018002562 A CL2018002562 A CL 2018002562A CL 2018002562 A CL2018002562 A CL 2018002562A CL 2018002562 A1 CL2018002562 A1 CL 2018002562A1
Authority
CL
Chile
Prior art keywords
involution
accelerate
drying
prevent infection
mammary glands
Prior art date
Application number
CL2018002562A
Other languages
English (en)
Inventor
Pierre Lacasse
Samuel Lanctôt
Patrick Fustier
André Begin
Ali R Taherian
Barbara Bisakowski
Original Assignee
Her Majesty The Queen In Right Of Canada As Represented By The Mini Of Agriculture And Agri Food
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Her Majesty The Queen In Right Of Canada As Represented By The Mini Of Agriculture And Agri Food filed Critical Her Majesty The Queen In Right Of Canada As Represented By The Mini Of Agriculture And Agri Food
Publication of CL2018002562A1 publication Critical patent/CL2018002562A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075—Macromolecular gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

UN MÉTODO PARA PREVENIR INFECCIÓN INTRAMAMARIA Y ACELERAR LA INVOLUCIÓN MEDIANTE ADMINISTRAR UN MODIFICADOR DE LA RESPUESTA BIOLÓGICA, ESPECÍFICAMENTE UNA SOLUCIÓN DE QUITOSANO, AL PEZÓN DE UN MAMÍFERO EN LACTACIÓN DURANTE EL SECADO. UNA SOLUCIÓN DE QUITOSANO NEUTRALIZADA CON UNA BASE DÉBIL TAL COMO ß-GLICEROFOSFATO PUEDE PERMANECER LÍQUIDA A TEMPERATURA AMBIENTE PARA SER INYECTADA DENTRO DE UN PEZÓN, PERO PUEDE FORMAR UN HIDROGEL A LA TEMPERATURA DEL CUERPO DENTRO DEL PEZÓN. LA SOLUCIÓN DE QUITOSANO NEUTRALIZADA PUEDE TAMBIÉN SER OPCIONALMENTE CO-ADMINISTRADA CON UN SELLANTE DE PEZONES.
CL2018002562A 2016-03-18 2018-09-07 Método para acelerar la involución e impedir la infección de glándulas mamarias en el secado. CL2018002562A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662310025P 2016-03-18 2016-03-18

Publications (1)

Publication Number Publication Date
CL2018002562A1 true CL2018002562A1 (es) 2019-02-15

Family

ID=59850126

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002562A CL2018002562A1 (es) 2016-03-18 2018-09-07 Método para acelerar la involución e impedir la infección de glándulas mamarias en el secado.

Country Status (11)

Country Link
US (1) US10828319B2 (es)
EP (1) EP3429601A4 (es)
CN (1) CN109310705A (es)
AU (1) AU2017233727A1 (es)
BR (1) BR112018068794A2 (es)
CA (1) CA3015846A1 (es)
CL (1) CL2018002562A1 (es)
CO (1) CO2018011133A2 (es)
MX (1) MX2018011350A (es)
RU (1) RU2018135961A (es)
WO (1) WO2017156632A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY37687A (es) * 2017-04-20 2018-11-30 Zoetis Services Llc Composiciones veterinarias para uso en tratamiento de mastitis y métodos asociados
BR112022010385A2 (pt) 2019-11-28 2022-08-23 Boehringer Ingelheim Vetmedica Gmbh Uso de inibidores de sglt-2 na secagem de mamíferos não humanos
CN111840212B (zh) * 2020-06-18 2023-07-21 余祖功 一种非人类动物用乳头封闭剂及其制备方法
CN120168507B (zh) * 2025-05-21 2025-09-19 中国农业大学 一种“回奶型”无抗干奶组合物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2212300A1 (en) 1997-08-04 1999-02-04 Abdellatif Chenite In vitro or in vivo gelfying chitosan and therapeutic uses thereof
DE60238858D1 (de) 2001-11-15 2011-02-17 Biosyntech Canada Inc Zusammensetzung und verfahren um chitosan unter neutralen bedingungen homogen zu modifizieren oder vernetzen
US20050191270A1 (en) * 2004-02-27 2005-09-01 Hydromer, Inc. Anti-infectious hydrogel compositions
WO2015093937A1 (en) * 2013-12-19 2015-06-25 N.V. Nutricia Lactobacillus salivarius for the treatment of mastitis
CA3002214C (en) 2015-11-03 2022-01-04 Zoetis Services Llc Sol-gel polymer composites and uses thereof

Also Published As

Publication number Publication date
RU2018135961A (ru) 2020-04-20
US20190060352A1 (en) 2019-02-28
BR112018068794A2 (pt) 2019-04-09
EP3429601A4 (en) 2019-11-27
CN109310705A (zh) 2019-02-05
AU2017233727A1 (en) 2018-09-13
CA3015846A1 (en) 2017-09-21
MX2018011350A (es) 2019-06-06
EP3429601A1 (en) 2019-01-23
WO2017156632A1 (en) 2017-09-21
US10828319B2 (en) 2020-11-10
CO2018011133A2 (es) 2018-10-31

Similar Documents

Publication Publication Date Title
CL2018002562A1 (es) Método para acelerar la involución e impedir la infección de glándulas mamarias en el secado.
EA201591761A1 (ru) Композиции на основе наночастиц
CL2016003056A1 (es) Dinucleótidos ciclicos moduladores de sting; composición y combinación farmacéutica que los comprende y uso de los mismos para el tratamiento de enfermedades tales como inflamación, enfermedades alérgicas y autoinmunes, enfermedades infecciosas y cancer.
MX2016010532A (es) Sistemas y metodos para cicatrizacion de tejido.
CL2014000045A1 (es) Metodo para reducir la carga microbiana de una composición liquida o viscosa que comprende someter dicha composicion a un tratamiento del campo electrico pulsado (pef); composicion que comprende moleculas bioactivas; y composicion tratada con campo electrico.
ES2533145R1 (es) Procedimiento cosmético para reducir el tejido adiposo subcutáneo
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
CR20140475A (es) Agentes terapéuticos para administración subcutánea optimizados
MX2016012248A (es) Composiciones para el tratamiento de autodigestion.
CY1122640T1 (el) Θεραπεια και προφυλαξη δερματιτιδας ακτινοβολιας
SV2017005444A (es) Método para tratar prevenir o reducir el riesgo de infección cutánea
AR102541A1 (es) Película autoadhesiva para la fumigación de suelos
MX2016014307A (es) Administración asistida de agentes de tratamiento de plantas.
AR097593A1 (es) Proceso para elaborar una composición líquida de limpieza
CL2016001130A1 (es) Composiciones sólidas de triglicéridos y usos de estas
MX386144B (es) Inmunopotenciador.
MX2018005566A (es) Dispositivo y metodo para el tratamiento de un implante oseo artificial con sangre.
MX2020008511A (es) Composicion antimicrobiana tixotropica.
AR105413A1 (es) Composición farmacéutica para el tratamiento de enfermedades gastrointestinales
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
MX372892B (es) Metodos y composiciones para el tratamiento de condiciones relacionadas con la falta del suministro de sangre, choque y lesiones neuronales.
RU2014125665A (ru) Способ наружного лечения микозов кожи
AR101582A1 (es) Tratamiento de tejido mamario con óxido nítrico
AR095401A1 (es) Método y composición del tratamiento de las semillas de canola